4/A: Framework Ventures Amends NBY Filing, Adds Key Reporting Person

Framework Ventures IV L.P. amended its Form 4 filing for NovaBay Pharmaceuticals, Inc. to include Michael Ernest Anderson as a reporting person, detailing significant preferred stock holdings convertible into common shares.

Summary

• Framework Ventures IV L.P. (Framework LP) amended its Form 4 filing for NovaBay Pharmaceuticals, Inc. (NBY) to add Michael Ernest Anderson as a reporting person.
• The amendment clarifies that Mr. Anderson, along with Framework Ventures GP IV LLC, Framework Ventures Management LLC, and Vance Spencer, are jointly filing the Form 4.
• Framework LP acquired 220,663 shares of Series D Non-Voting Convertible Preferred Stock and the rights to purchase 134,375 shares of Series E Non-Voting Convertible Preferred Stock from David Lazar on October 9, 2025.
• Following stockholder approvals on October 16, 2025, each share of Series D and Series E Preferred Stock will automatically convert into 160 shares of common stock.
• This conversion represents a potential total of 35,306,080 common shares from Series D and 21,500,000 common shares from Series E, totaling 56,806,080 common shares.

Sentiment

Score: 7

Explanation: The filing indicates significant institutional investment and a clear path to conversion, suggesting confidence from Framework Ventures. However, the large potential dilution from conversion could be a concern for existing common shareholders.

Positives

• Increased transparency with the addition of Michael Ernest Anderson as a reporting person, ensuring comprehensive disclosure of beneficial ownership.
• Significant institutional investment by Framework Ventures, a 10% owner, potentially signaling confidence in NovaBay Pharmaceuticals' long-term prospects.
• The conversion of preferred stock into common stock will simplify the company's capital structure over time.

Negatives

• Potential for significant dilution of existing common shareholders upon the conversion of 56,806,080 preferred shares into common stock.

Risks

• Dilution risk for existing common shareholders due to the conversion of a large number of preferred shares into common stock.
• The value of the common stock could be negatively impacted by the increased supply from the conversion of preferred shares.

Future Outlook

The Series D Preferred Stock is expected to automatically convert into common stock within three business days of the October 16, 2025 meeting, and the Series E Preferred Stock within thirty business days of the meeting, significantly increasing the number of common shares outstanding.

Management Comments

• Framework Entities disclaim beneficial ownership of these shares, except to the extent of its or his pecuniary interest in such shares, if any.

Industry Context

This filing reflects continued institutional investor interest in the biotechnology and pharmaceutical sector, with Framework Ventures, a venture capital firm, making a significant investment in NovaBay Pharmaceuticals. Such investments often signal confidence in a company's long-term prospects, particularly in early-stage or growth-oriented biotech firms, but also introduce potential for capital structure changes.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Related Party Transactions

• Framework Ventures IV L.P., a 10% owner and entity with director representation, acquired preferred stock from David Lazar. While not a direct transaction with NovaBay, it involves a significant shareholder and impacts NovaBay's capital structure.

Stakeholder Impact

• Shareholders: Potential for significant dilution of common stock value due to the conversion of preferred shares. Increased institutional ownership by Framework Ventures could be seen as a positive signal.
• Company (NovaBay): Simplification of capital structure as preferred shares convert to common.

Next Steps

• Automatic conversion of 220,663 shares of Series D Preferred Stock into 35,306,080 common shares within three business days of October 16, 2025.
• Automatic conversion of 134,375 shares of Series E Preferred Stock into 21,500,000 common shares within thirty business days of October 16, 2025.

Key Dates

Recommendation

While the significant institutional investment by Framework Ventures indicates a degree of confidence in NovaBay, the potential for substantial dilution from the conversion of over 56 million preferred shares into common stock introduces considerable uncertainty. Investors should hold and monitor the impact of this conversion on the common stock price and the company's overall valuation before making further investment decisions. The filing itself is an amendment for compliance, not a new operational update.

Keywords

NovaBay Pharmaceuticals, NBY, Framework Ventures, SEC Form 4/A, Beneficial Ownership, Convertible Preferred Stock, Stock Conversion, Institutional Investment, Share Dilution, Corporate Governance